MicroPort®

MicroPort Scientific Corporation

微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

ESTIMATED INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026

This announcement is made by MicroPort Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors of the Company hereby inform holders of the shares and securities of the Company and potential investors that, based on the preliminary assessment of the Group's unaudited consolidated financial statements and the information currently available, the Group's performance for the six months ended 30 June 2026 (the "**Period**") is expected to be as follows:

(i) The revenue from the Group's continuing operations[1] achieved a year-on-year growth of approximately 12% to 14%, with its overseas business[2] in particular continuing to deliver a strong growth of approximately 140%[3].

(ii) The Group's profitability at the operating level has steadily improved, with gross profit margin of the continuing operations[1] increasing by approximately 3 to 4 percentage points year-on-year, and the Group continued to advance refined operations and expense control. During the Period, the continuing operations[1] recorded an operating net profit[4] of not less than US$24 million (for the six-month period ended 30 June 2025: an operating net loss[4] from the continuing operations[1] of US$13 million).

1 As at the end of 2025, MicroPort NeuroScientific Corporation and its subsidiaries (the "**NeuroScientific Group**") were no longer included in the scope of the Group's consolidated financial statements. To reflect the performance and changes of the Group's continuing operations, the comparative figures for the same period of the previous year have been restated accordingly to exclude the impact of the NeuroScientific Group. The results of the Company (with the impact of the NeuroScientific Group included) for the same period of the previous year are set out in the interim results announcement of the Company dated 29 August 2025 and the interim report of the Company published on 25 September 2025.

2 Represent the business of selling products that have received R&D and marketing approval in China by the Group in overseas markets.

3 The revenue growth rates set out in this announcement have excluded the impact of foreign exchange fluctuations.

4 Operating net profit/(loss) is derived from gross profit less research and development costs, distribution costs and administrative expenses.

(iii) However, due to the finance costs of approximately US$43 million incurred during the Period, together with the effect of one-off/non-cash factors including (a) foreign exchange fluctuations, (b) fair value revaluation of convertible loans, and (c) one-off losses arising from impairment of certain assets and transactions, the Group's continuing operations[1] are expected to record a net loss of not more than US$50 million for the Period (for the six-month period ended 30 June 2025: a net loss from the continuing operations[1] of US$49 million).

As at the date of this announcement, in respect of the expected net loss for the Period, the Company has obtained a waiver in respect of the financial covenants applicable to the Period under the agreements relating to the convertible loans. In the future, the Group will consistently adhere to the "focus on core" strategy, seek mutually beneficial strategic solutions for its non-core/loss-making businesses, and properly arrange and continuously optimize the Group's debt terms and structure, so as to further improve the Group's operating conditions and financial performance.

As at the date of this announcement, the Company is still in the process of preparing and completing the interim results of the Group for the six months ended 30 June 2026 (the "**2026 Interim Results**"). The information contained in this announcement is based on a preliminary assessment of the business operation information currently available to the Board and is not based on any financial data or data which has been audited or reviewed by the independent auditors or audit committee of the Company. Holders of the shares and securities of the Company and potential investors are advised to carefully read the Company's announcement for the 2026 Interim Results, which is expected to be published by the end of August 2026. Holders of the shares and securities of the Company and potential investors are advised to exercise caution when dealing in the shares and securities of the Company.

By order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 12 August 2026

As at the date of this announcement, the executive Director of the Company is Dr. Zhaohua Chang; the non-executive Directors of the Company are Dr. Feng Gu, Dr. Qingbing Men and Ms. Weiqin Sun; and the independent non-executive Directors of the Company are Mr. Jonathan H. Chou, Dr. Guoen Liu, Mr. Chunyang Shao and Dr. Yingyao Chen.

* *For identification purpose only*